---
document_datetime: 2025-12-02 05:03:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dabigatran-etexilate-teva.html
document_name: dabigatran-etexilate-teva.html
version: success
processing_time: 0.1122707
conversion_datetime: 2025-12-28 14:26:27.03242
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)

[RSS](/en/individual-human-medicine.xml/101557)

##### Authorised

This medicine is authorised for use in the European Union

dabigatran etexilate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)](#news-on)
- [More information on Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Dabigatran etexilate Teva is an anticoagulant medicine (a medicine that prevents blood clotting) used for:

- preventing the formation of blood clots in the veins in adults who have had an operation to replace a hip or knee;
- preventing stroke (caused by a blood clot in the brain) and systemic embolism (a blood clot in another organ) in adults who have an abnormal heartbeat called 'non-valvular atrial fibrillation' and are considered to be at risk of stroke;
- treating deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (PE, a blood clot in a blood vessel supplying the lungs) in adults, and preventing these conditions from occurring again;
- treating blood clots in veins in children and preventing them from occurring again.

Dabigatran etexilate Teva contains the active substance dabigatran etexilate.

Dabigatran etexilate Teva is a 'generic medicine'. This means that it contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Dabigatran etexilate Teva is Pradaxa. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Dabigatran etexilate Teva used?

Dabigatran etexilate Teva can only be obtained with a prescription. The medicine is taken by mouth and is available in different forms depending on the patient's age. The dose and duration of treatment depend on the condition the medicine is being used to treat, the patient's age and kidney function, and other medicines the patient is taking. For children the dose also depends on their weight.

All patients at increased risk of bleeding should be monitored closely and the doctor may reduce the dose of Dabigatran etexilate Teva.

Kidney function should be assessed before starting treatment to exclude patients with severely reduced kidney function and should be re-assessed during treatment if any worsening is suspected. When Dabigatran etexilate Teva is used long term in patients with non-valvular atrial fibrillation, or when it is used in patients with DVT or PE, kidney function should be assessed at least once a year in patients whose kidney function is mildly to moderately reduced or who are over 75 years old.

For more information about using Dabigatran etexilate Teva, see the package leaflet or contact your doctor or pharmacist.

## How does Dabigatran etexilate Teva work?

The active substance in Dabigatran etexilate Teva, dabigatran etexilate, is a prodrug of dabigatran. This means that it is converted into dabigatran in the body. Dabigatran is an anticoagulant, meaning that it prevents the blood from coagulating (clotting). It blocks a substance called thrombin, which plays an important role in blood clotting.

## How has Dabigatran etexilate Teva been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Pradaxa, and do not need to be repeated for Dabigatran etexilate Teva.

As for every medicine, the company provided studies on the quality of Dabigatran etexilate Teva. The company also carried out two studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Dabigatran etexilate Teva?

Because Dabigatran etexilate Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

For the list of side effects and restrictions with Dabigatran etexilate Teva, see the package leaflet.

## Why is Dabigatran etexilate Teva authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Dabigatran etexilate Teva has been shown to have comparable quality and to be bioequivalent to Pradaxa. Therefore, the Agency's view was that, as for Pradaxa, the benefits of Dabigatran etexilate Teva outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Dabigatran etexilate Teva?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dabigatran etexilate Teva have been included in the summary of product characteristics and the package leaflet.

Any additional measures in place for Pradaxa, such as a patient card with key safety information, also apply to Dabigatran etexilate Teva where appropriate.

As for all medicines, data on the use of Dabigatran etexilate Teva are continuously monitored. Suspected side effects reported with Dabigatran etexilate Teva are carefully evaluated and any necessary action taken to protect patients.

## Other information about Dabigatran etexilate Teva

Dabigatran etexilate Leon Farma received a marketing authorisation valid throughout the EU on 19 February 2024.

The name of the medicine was changed to Dabigatran etexilate Teva on 19 August 2024.

Dabigatran etexilate Teva : EPAR - Medicine overview

Reference Number: EMA/390607/2024

English (EN) (149.25 KB - PDF)

**First published:** 21/03/2024

**Last updated:** 30/01/2025

[View](/en/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-210)

български (BG) (237.17 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/bg/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_bg.pdf)

español (ES) (238.38 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/es/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_es.pdf)

čeština (CS) (260.37 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/cs/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_cs.pdf)

dansk (DA) (236.04 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/da/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_da.pdf)

Deutsch (DE) (240.88 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/de/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_de.pdf)

eesti keel (ET) (234.9 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/et/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_et.pdf)

ελληνικά (EL) (263.78 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/el/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_el.pdf)

français (FR) (238.63 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/fr/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_fr.pdf)

hrvatski (HR) (258.38 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/hr/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_hr.pdf)

italiano (IT) (237.02 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/it/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (268.44 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/lv/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (260.75 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/lt/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_lt.pdf)

magyar (HU) (259.16 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/hu/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_hu.pdf)

Malti (MT) (261.99 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/mt/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_mt.pdf)

Nederlands (NL) (237.91 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/nl/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_nl.pdf)

polski (PL) (262.45 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/pl/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_pl.pdf)

português (PT) (238.93 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/pt/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_pt.pdf)

română (RO) (259.78 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/ro/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_ro.pdf)

slovenčina (SK) (260.54 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/sk/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_sk.pdf)

slovenščina (SL) (256.69 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/sl/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_sl.pdf)

Suomi (FI) (235.28 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/fi/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_fi.pdf)

svenska (SV) (235.82 KB - PDF)

**First published:**

21/03/2024

**Last updated:**

30/01/2025

[View](/sv/documents/overview/dabigatran-etexilate-teva-epar-medicine-overview_sv.pdf)

Dabigatran Etexilate Leon Farma : EPAR - Risk management plan

English (EN) (511.17 KB - PDF)

**First published:** 21/03/2024

**Last updated:** 26/09/2024

[View](/en/documents/rmp/dabigatran-etexilate-leon-farma-epar-risk-management-plan_en.pdf)

## Product information

Dabigatran Etexilate Teva : EPAR - Product information

English (EN) (1.46 MB - PDF)

**First published:** 21/03/2024

**Last updated:** 21/01/2025

[View](/en/documents/product-information/dabigatran-etexilate-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-372)

български (BG) (2.58 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/bg/documents/product-information/dabigatran-etexilate-teva-epar-product-information_bg.pdf)

español (ES) (2.39 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/es/documents/product-information/dabigatran-etexilate-teva-epar-product-information_es.pdf)

čeština (CS) (1.75 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/cs/documents/product-information/dabigatran-etexilate-teva-epar-product-information_cs.pdf)

dansk (DA) (2.26 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/da/documents/product-information/dabigatran-etexilate-teva-epar-product-information_da.pdf)

Deutsch (DE) (2.51 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/de/documents/product-information/dabigatran-etexilate-teva-epar-product-information_de.pdf)

eesti keel (ET) (2.53 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/et/documents/product-information/dabigatran-etexilate-teva-epar-product-information_et.pdf)

ελληνικά (EL) (2.46 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/el/documents/product-information/dabigatran-etexilate-teva-epar-product-information_el.pdf)

français (FR) (2.58 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/fr/documents/product-information/dabigatran-etexilate-teva-epar-product-information_fr.pdf)

hrvatski (HR) (2.82 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/hr/documents/product-information/dabigatran-etexilate-teva-epar-product-information_hr.pdf)

íslenska (IS) (1.63 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/is/documents/product-information/dabigatran-etexilate-teva-epar-product-information_is.pdf)

italiano (IT) (2.15 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/it/documents/product-information/dabigatran-etexilate-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.86 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/lv/documents/product-information/dabigatran-etexilate-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.93 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/lt/documents/product-information/dabigatran-etexilate-teva-epar-product-information_lt.pdf)

magyar (HU) (1.59 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/hu/documents/product-information/dabigatran-etexilate-teva-epar-product-information_hu.pdf)

Malti (MT) (3.28 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/mt/documents/product-information/dabigatran-etexilate-teva-epar-product-information_mt.pdf)

Nederlands (NL) (2.95 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/nl/documents/product-information/dabigatran-etexilate-teva-epar-product-information_nl.pdf)

norsk (NO) (1.54 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/no/documents/product-information/dabigatran-etexilate-teva-epar-product-information_no.pdf)

polski (PL) (2.62 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/pl/documents/product-information/dabigatran-etexilate-teva-epar-product-information_pl.pdf)

português (PT) (2.23 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/pt/documents/product-information/dabigatran-etexilate-teva-epar-product-information_pt.pdf)

română (RO) (2.74 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/ro/documents/product-information/dabigatran-etexilate-teva-epar-product-information_ro.pdf)

slovenčina (SK) (1.72 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/sk/documents/product-information/dabigatran-etexilate-teva-epar-product-information_sk.pdf)

slovenščina (SL) (1.59 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/sl/documents/product-information/dabigatran-etexilate-teva-epar-product-information_sl.pdf)

Suomi (FI) (1.63 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/fi/documents/product-information/dabigatran-etexilate-teva-epar-product-information_fi.pdf)

svenska (SV) (2.41 MB - PDF)

**First published:**

21/03/2024

**Last updated:**

21/01/2025

[View](/sv/documents/product-information/dabigatran-etexilate-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0005/G 20/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dabigatran Etexilate Teva : EPAR - All authorised presentations

English (EN) (125.73 KB - PDF)

**First published:** 31/05/2024

**Last updated:** 21/01/2025

[View](/en/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-555)

български (BG) (141.62 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/bg/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (127.73 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/es/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (148.1 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/cs/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (122.04 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/da/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (126.56 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/de/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (126.32 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/et/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (155.37 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/el/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (132.13 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/fr/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (145.85 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/hr/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (125.26 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/is/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (128.21 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/it/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (147.03 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/lv/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (152.43 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/lt/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (154.65 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/hu/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (146.58 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/mt/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (124.12 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/nl/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (122.01 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/no/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (149.29 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/pl/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (130.76 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/pt/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (152.38 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/ro/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (147.91 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/sk/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (135.06 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/sl/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (125.89 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/fi/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (129.98 KB - PDF)

**First published:**

31/05/2024

**Last updated:**

21/01/2025

[View](/sv/documents/all-authorised-presentations/dabigatran-etexilate-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma) Active substance dabigatran etexilate mesilate International non-proprietary name (INN) or common name dabigatran etexilate Therapeutic area (MeSH)

- Venous Thromboembolism
- Arthroplasty, Replacement

Anatomical therapeutic chemical (ATC) code B01AE07

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

**Dabigatran etexilate Leon Farma 75 mg**

Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age.

**Dabigatran etexilate Leon Farma 110 mg**

Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent

DVT and PE in adults.

Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than

18 years of age.

**Dabigatran etexilate Leon Farma 150 mg**

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults

Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age.

## Authorisation details

EMA product number EMEA/H/C/005922

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva GmbH

Graf-Arco-Straße 3

Marketing authorisation issued 19/02/2024 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dabigatran etexilate Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (109.18 KB - PDF)

**First published:** 18/04/2024

**Last updated:** 21/01/2025

[View](/en/documents/procedural-steps-after/dabigatran-etexilate-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Dabigatran Etexilate Leon Farma : EPAR - Public assessment report

Adopted

Reference Number: EMA/12212/2024

English (EN) (1.09 MB - PDF)

**First published:** 21/03/2024

[View](/en/documents/assessment-report/dabigatran-etexilate-leon-farma-epar-public-assessment-report_en.pdf)

CHMP initial authorisation summary of positive opinion for Dabigatran Etexilate Leon Farma

Adopted

Reference Number: EMA/CHMP/556286/2023

English (EN) (187.31 KB - PDF)

**First published:** 15/12/2023

[View](/en/documents/smop-initial/chmp-initial-authorisation-summary-positive-opinion-dabigatran-etexilate-leon-farma_en.pdf)

#### News on Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023) 15/12/2023

#### More information on Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)

- [Exploring mediation through major bleeding between direct oral anticoagulants and cardiovascular events (MB mediation in CV RWE) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000168)

**This page was last updated on** 21/01/2025

## Share this page

[Back to top](#main-content)